Self-reported adverse events after 2 doses of COVID-19 vaccine in Korea

• DOI: 10.4178/epih.e2023006
• Publication Date: 2023-01-06T01:29:40Z
• Authors: Yunhyung Kwon; Insob Hwang; Mijeong Ko; Hyungjun Kim; Seontae Kim; Soon-Young Seo; Enhi Cho; Yeon-Kyeng Lee
• Keywords: 2019-20 coronavirus outbreak; Betacoronavirus; Pandemic

In Korea, a national coronavirus disease 2019 (COVID-19) vaccination program was implemented, including 4 vaccines against COVID-19. A text messaging-based survey, in addition to passive adverse event reporting system, launched quickly report unusual symptoms post-vaccination. This study compared the frequency of events after COVID-19 based on vaccine type and 2-dose regimen (homologous or heterologous).Self-reported were collected through text-message survey for 7 days each vaccination. included 50,950 recipients who responded at least once. Informed consent receive surveys via obtained from date first vaccination.The mRNA reported local systemic reactions 1.6 times 2.8 more frequently dose 2 than 1 (p<0.001), whereas ChAdOx1-S significantly fewer (p<0.001). Local approximately frequent heterologous BNT162b2/BNT162b2 ChAdOx1-S/ChAdOx1-S regimens, respectively. Young individuals, female, those receiving regimens ChAdOx1-S/BNT162b2 older participants, male, with homologous regimens.Although regimen, youth, female sex associated higher risk vaccination, no critical issues noted. Active consideration schedules evidence efficacy safety appears desirable.